Data from the multicenter, prospective trial also show the Cook DES achieved 86.6 percent event-free survival at 24-months.
Rob Lyles, global leader and vice president of Cook Medical’s Peripheral Intervention division said, This clinical trial was rigorously designed to lend real-world perspective to the current treatment landscape of PAD, and we are excited by the results we have thus far collected. At Cook, we’re committed to delivering technologies that advance minimally invasive health care for as wide a patient population as possible.
PAD, also called “hardening” of the arteries or atherosclerosis, occurs when fatty deposits and inflammation reduce the blood supply to the extremities. PAD occurs in as many as one in five Americans over the age of 65, yet just a quarter of those receive treatment¹.
The world’s largest study of its kind, the randomized trial is complemented by a global single-arm registry involving 787 patients, including diabetics, symptomatic patients and those with complex lesions. The Zilver PTX Drug Eluting Stent is an investigational device not approved for sale in the United States.
About the International Symposium on Endovascular Therapy (ISET):
Now in its 21st year, the leader in interventional education continues to meet the needs of physicians who recognize the challenges that lie ahead and actively seek the knowledge to meet those challenges. ISET provides the tools – in the form of unbiased, professional education – to lead practitioners into the future of an ever-evolving field. For more information, visit www.iset.org.
About Cook Medical
Founded in 1963, Cook Medical pioneered many of the medical devices now commonly used to perform minimally invasive medical procedures throughout the body. Today, the company integrates medical devices, drugs and biologics to enhance patient safety and improve clinical outcomes. Since its inception, Cook has operated as a family-held private corporation. For more information, visit www.cookmedical.com. Follow Cook Medical on Twitter @cookmedicalpr and @cookvascular.